biotech firesales Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Ian@SI

10/27/2015 8:20:06 PM

of 3661

MCUR off almost 70% AH. Volume only 2000 shares.

After Hours Volume: After Hours High: After Hours Low:

2,000

$ 1.95
(17:55:29 PM)

$ 1.41
(19:17:37 PM)

Read more: nasdaq.com

Macrocure announces that results from a pivotal Phase 3 study of CureXcell in the treatment of diabetic foot ulcers did not meet its primary endpoint or secondary endpoints (shares halted) ( MCUR) : The co announced that results from a pivotal Phase 3 multicenter, randomized, double-blind, parallel-group, sham-controlled study (MC-102) of CureXcell in the treatment of diabetic foot ulcers did not meet its primary endpoint. CureXcell, the Company's lead product candidate, did not show a statistically significant proportion of subjects with complete closure at 16 weeks and sustained complete closure for four additional weeks. In addition, CureXcell did not meet the secondary endpoints of the study.

As of September 30, 2015, the Company had a preliminary estimated and unaudited cash balance of approximately $30 million with no debt outstanding.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next